PPD has units in Moscow, Smolensk and St. Petersburg, which in addition to sites it gained with the acquisition of AbCRO in 2009 and InnoPharm, makes it one of the largest players in Central and Eastern Europe (CEE).
Roger Newbery, PPD’s VP of clinical development in Europe, the Middle East and Africa, said the new office will help “reach more than five million people and grow our number of investigator sites to meet growing client demand.”
News of the Novosibirsk also office follows a week after PPD became a strategic partner for GlaxoSmithKline (GSK) which, given the UK firm’s efforts to target emerging markets, is likely to have factored in the decision to invest.